Blois Shauna L, Cuq Benoît Y, Bienzle Dorothee
Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
PLoS One. 2025 Jun 17;20(6):e0326341. doi: 10.1371/journal.pone.0326341. eCollection 2025.
Immune-mediated hematologic diseases (IMHD) including immune-mediated hemolytic anemia (IMHA) and immune thrombocytopenia (ITP) can cause severe disease in dogs. The underlying immune system abnormalities associated with these conditions is not known. The hypotheses of this study were that dogs with IMHD would have increased frequencies of CD4+ and CD8 + lymphocytes, decreased frequencies and numbers of T regulatory cells, and increased frequencies of interleukin (IL)-17 + lymphocytes. Fifteen dogs with newly diagnosed IMHA or ITP and 15 healthy control dogs were recruited for this prospective study. Flow cytometry was used to enumerate CD4 + lymphocytes, CD8 + lymphocytes, T regulatory (CD4 + CD25 + Foxp3+) cells, and lymphocytes secreting IL-17 in dogs with IMHD at diagnosis, then 2 and 4 days after starting immunosuppressive treatment. Median proportion of CD4+ (Day 0: 3.4%, Day 2: 3.3%) and CD8+ (Day 0: 1%, Day 2: 0.6%) cells was lower in dogs with IMHD compared to control dogs (CD4 + 22.8%, CD8 + : 13.6%; P < 0.0001 for each). Additionally, T regulatory cells were reduced in IMHD dogs at Day 0 (0.2% versus 0.6% of total lymphocytes, P = 0.0025). Dogs with IMHD had a higher proportion of lymphocytes positive for IL-17 at Day 2 (1.3%) compared to control dogs (0.4%, P = 0.0024). Dogs with IMHD have immune system alterations at diagnosis and during early treatment characterized by a deficiency in T regulatory cells and an increase in IL-17 + lymphocyte. These changes might contribute to the pathogenesis of IMHA and ITP.
免疫介导的血液系统疾病（IMHD），包括免疫介导的溶血性贫血（IMHA）和免疫性血小板减少症（ITP），可在犬类中引发严重疾病。与这些病症相关的潜在免疫系统异常尚不清楚。本研究的假设是，患有IMHD的犬类会出现CD4+和CD8+淋巴细胞频率增加、调节性T细胞频率和数量减少以及白细胞介素（IL）-17+淋巴细胞频率增加的情况。15只新诊断为IMHA或ITP的犬类和15只健康对照犬被纳入这项前瞻性研究。在诊断时以及开始免疫抑制治疗后的第2天和第4天，采用流式细胞术对患有IMHD的犬类中的CD4+淋巴细胞、CD8+淋巴细胞、调节性T（CD4+CD25+Foxp3+）细胞以及分泌IL-17的淋巴细胞进行计数。与对照犬（CD4+：22.8%，CD8+：13.6%）相比，患有IMHD的犬类中CD4+细胞（第0天：3.4%，第2天：3.3%）和CD8+细胞（第0天：1%，第2天：0.6%）的中位数比例更低（每项P<0.0001）。此外，在第0天，IMHD犬类中的调节性T细胞减少（占总淋巴细胞的0.2%对0.6%，P=0.0025）。与对照犬（0.4%，P=0.0024）相比，患有IMHD的犬类在第2天IL-17阳性淋巴细胞的比例更高（1.3%）。患有IMHD的犬类在诊断时和早期治疗期间存在免疫系统改变，其特征为调节性T细胞缺乏和IL-17+淋巴细胞增加。这些变化可能有助于IMHA和ITP的发病机制。
